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Abstract 
Review on Anaplastic large cell lymphoma, ALK-
negative, with data on clinics, and the genes 
involved. 
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Disease 
Anaplastic large cell lymphoma (ALCL), ALK-
negative is a CD30-positive T-cell non-Hodgkin 
lymphoma that by definition resembles ALCL, 
ALK-positive but lacks ALK expression (Mason, 
Harris et al. 2008).  
ALCL, ALK-negative was classified as a provisional 
entity distinct from ALCL, ALK-positive in the 2008 
WHO classification, and is anticipated to be 
upgraded to a definite entity in the 2016 WHO 
update (Swerdlow, Campo et al. 2016). 
Etiology 
The etiology of ALCL, ALK negative is unknown. 
Epidemiology 
ALCL, ALK-negative makes up between 2.6% and 
9.4% of T-/NK-cell non-Hodgkin lymphomas, with 
the lowest proportion occurring in Asia and the 
highest in Europe (Vose, Armitage et al. 2008). 
ALCL, ALK-negative generally occurs in older 
patients, with a median age of diagnosis of 55-60 
years, compared to 25-35 years for ALK-positive 
ALCL (Ferreri, Govi et al. 2013).  
Males are affected more commonly than females 
(M:F, ~1.5:1). 
Clinics 
Patients with ALCL, ALK-negative typically present 
with lymphadenopathy, often with stage III/IV 
disease, and B symptoms (ten Berge, de Bruin et al. 
2003). Extranodal sites also may be involved, 
including skin, bone, and soft tissues. Secondary 
cutaneous involvement by ALCL, ALK-negative 
must be distinguished from primary cutaneous 
ALCL, which is a distinct entity (Bekkenk, Geelen 
et al. 2000). 
Pathology 
By definition, the morphologic appearance is similar 
to that seen in ALCL, ALK-positive (Mason, Harris 
et al. 2008). Specifically, most cases resemble the 
so-called "common" pattern of ALK, ALK-positive 
and show sheet-like growth of tumor cells, 
sometimes sparing residual lymphoid follicles 
(Delsol, Falini et al. 2008). Sinusoidal involvement 
is common, and cohesive clusters of intrasinusoidal 
tumor cells may mimic metastatic carcinoma. The 
tumor cells typically are large and may show 
significant pleomorphism. So-called "hallmark" 
cells, with horseshoe-shaped or reniform nuclei, 
always can be identified (Benharroch, Meguerian-
Bedoyan et al. 1998). Immunophenotyping studies 
are essential to the diagnosis of ALCL, ALK-
negative. All cases express CD30 by definition. 
Aberrant loss of pan-T-cell antigen expression is 
common, and about two-thirds of cases express 
cytotoxic proteins (TIA1, granzyme B, or perforin) 
(Savage, Harris et al. 2008). ALK protein is absent. 
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ALCL, ALK-negative. The tumor is composed of sheets of large pleomorphic cells, some with horseshoe-shaped nuclei 
("hallmark" cells; H&E, top). By immunohistochemical stains the tumor cells are negative for the B-cell marker, CD20; positive for 
the T-cell marker, CD3; positive for CD30; and negative for ALK. 
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Treatment 
ALCL, ALK-negative is typically treated with 
CHOP (cyclophosphamide, doxorubicin, vincristine, 
and prednisone) or CHOP-like chemotherapy, often 
followed by autologous stem cell transplantation 
(Bennani-Baiti, Ansell et al. 2016). New targeted 
agents such as brentuximab vedotin and histone 
deacetylase inhibitors have demonstrated efficacy in 
relapsed and refractory disease. 
Prognosis 
The prognosis for ALCL, ALK-negative is poorer 
than for ALCL, ALK-positive, with a 5-year overall 
survival (OS) rate of 49% compared to 70% for the 
latter (Savage, Harris et al. 2008). However, 
prognosis is better than for most other types of T-cell 
non-Hodgkin lymphomas, including peripheral T-
cell lymphoma, not otherwise specified (PTCL, 
NOS). Recent data have shown that ALCL, ALK-
negative is a genetically heterogeneous disease, and 
that outcomes vary widely based on genetic subtype 
(Parrilla Castellar, Jaffe et al. 2014). Specifically, 5-
year OS was very good (90%) in patients carrying 
DUSP22 rearrangements, poor (17%) in TP63/ -
rearranged cases, and intermediate (42%) in patients 
lacking ALK/, DUSP22, and TP63 rearrangements. 
Genetics 
Recurrent somatic mutations in the JAK1/ and/or 
STAT3/ genes have been reported in 18% of ALCL, 
ALK-negative (Crescenzo, Abate et al. 2015).  JAK1 
mutations were most commonly G1097D/S, while 




Copy number losses involving PRDM1 (6q21) 
and/or TP53/ (17p13) are recurrent in ALCL, ALK-
negative, and have been associated with poor 
survival (Boi, Rinaldi et al. 2013).  
Recurrent chromosomal rearrangements involving 
the DUSP22 -IRF4/  locus on 6p25.3 are present in 
~30% of ALCL, ALK-negative (Feldman, Law et al. 
2009; Feldman, Dogan et al. 2011; Parrilla Castellar, 
Jaffe et al. 2014).  The most common partner is a 
non-genic region on 7q32.3.  DUSP22 
rearrangements are associated with decreased 
expression of the dual-specificity phosphatase gene, 
DUSP22; lack of cytotoxic marker expression; 
favorable prognosis; and distinct morphologic 
features (King, Dao et al. 2016).  
Rearrangements involving TP63, most often 
partnering with TBL1XR1/ occur in ~8% of ALCL, 
ALK-negative and have been associated with poor 
prognosis (Vasmatzis, Johnson et al. 2012; Parrilla 
Castellar, Jaffe et al. 2014). 
Gene fusions involving tyrosine kinase genes other 
than ALK have been reported in ALCL, ALK-
negative, including TYK2 (t(10;19)(q24;p13) 
(NFKB2/TYK2), t(1;19)(p34;p13) 
(PABPC4/TYK2) and ROS1 (t(6;10)(q22;q24) 
(NFKB2/ROS1),  (NCOR2/ROS1)(Crescenzo, 
Abate et al. 2015). 
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